A Phase II, Study to Evaluate The Efficacy and Safety of Dantonic 'Registered trade mark' in Patients with Chronic Stable Angina Pectoris

CNS Pty Ltd0 sites70 target enrollmentJanuary 20, 2009

ConditionsChronic Stable Angina Pectoris Angina Cardiovascular - Coronary heart disease

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Chronic Stable Angina Pectoris
Sponsor: CNS Pty Ltd
Enrollment: 70
Status: Terminated
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 20, 2009

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

CNS Pty Ltd

Eligibility Criteria

Inclusion Criteria

•1\.Male or female aged 18 to 80 years.
•2\.Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator’s opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.
•3\.Evidence of coronary artery disease that consists of a well\-documented medical history of myocardial infarction or significant coronary artery disease with non\-invasive or angiographic confirmation.
•4\.Symptoms that support the diagnosis of chronic stable angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph changes.
•5\.Moderate (Class II or Class III according to Canadian Cardiovascular Society Angina Classification) angina pectoris
•6\.Naive patient or patient who’s Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day \-7 and day 0\.
•7\.Patient must be able to withdraw all anti\-angina regimen (except short\-acting nitroglycerin, beta\-blockers or calcium channel blockers), that were used prior to this initial visit.
•8\.Patient must understand and be willing to comply with protocol visit schedule.
•9\.Patient must be able and willing to give informed consent.

Exclusion Criteria

•1\.Contraindication to perform treadmill Exercise Tolerance Test (ETT).
•2\.Presence of pre\-exercise ST\-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff\-Parkinson\-White (WPW) syndrome or other factors that could, to the investigator’s opinion, interfere with exercise electrocardiograph interpretation.
•3\.Clinically severe arrhythmias or atrioventricular conduction block greater than first degree.
•4\.Clinically severe co\-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, current of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.
•5\.Recent history of congestive heart failure (occurrence within two weeks), unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.
•6\.Current bleeding diathesis, or current treatment with warfarin and/or on other oral anticoagulants, and inability to discontinue these medications.
•7\.Implanted pacemaker.
•8\.Aspirin and/or other platelet inhibitors including Clopidogrel, started less than 30 days prior to the signing of informed consent.
•9\.Pregnancy or lactation.
•10\.Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and other anti\-angina medications except for beta\-blockers or calcium channel blockers.